GlassScriptPhysician profile
Scott A Russell
NPI 1073581237
$3,905.49
in general payments reported to CMS, 2019-2025
27 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $136 · 2021: $621 · 2022: $348 · 2023: $431 · 2024: $1,165 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.34 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $656.56 | 2024-2025 | Apretude, Rukobia, Dovato |
| Amgen INC. | $502.54 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $432.53 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $305.97 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $261.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $214.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $196.12 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $166.76 | 2019-2020 | |
| Edwards Lifesciences Corporation | $150.02 | 2021 | |
| Gilead Sciences, INC. | $149.58 | 2019-2025 | Descovy |
| Si-Bone, INC. | $133.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $124.78 | 2021 | |
| Pfizer INC. | $104.35 | 2022-2025 | |
| Theratechnologies INC. | $104.20 | 2024 | Trogarzo |
| Abbott Laboratories | $86.86 | 2023-2024 | Proclaim, Octrode |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $55.92 | 2019-2024 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $49.64 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.91 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $27.99 | 2024 | Nuedexta |
| Radius Health, INC. | $24.68 | 2023 | Tymlos |
| Scilex Pharmaceuticals INC. | $21.83 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.98 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Welireg |
| Novartis Pharmaceuticals Corporation | $16.42 | 2022 | |
| Amarin Pharma, INC. | $14.12 | 2021 | |
| Abbvie INC. | $13.41 | 2023 | Ubrelvy |
| Dynavax Technologies Corporation | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.